- In January 2024, Fresenius Kabi announced the launch of Posaconazole Injection, a generic alternative to Noxafil, for treating or preventing serious fungal infections in adults and children with weakened immune systems. Available in the U.S., this product is the newest addition to Fresenius Kabi’s portfolio, which includes over 30 anti-infective molecules
- In December 2023, Aurobindo Pharma Ltd revealed that its wholly-owned subsidiary, Eugia Pharma Specialities Ltd, received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market its generic version of Posaconazole Injection. The approval covers the 300 mg/16.7 mL (18 mg/mL) single-dose vial used for preventing serious fungal infections
- In April 2022, Dr. Reddy’s Laboratories Ltd. and its subsidiaries launched Posaconazole Delayed-Release Tablets, 100 mg, a therapeutic generic equivalent of NOXAFIL (posaconazole) Delayed-Release Tablets, approved by the U.S. Food and Drug Administration (USFDA)
- In February 2021, Lupin Ltd launched its generic equivalent of Noxafil delayed-release tablets, Posaconazole Delayed-Release Tablets, 100 mg. The drug is used for the prevention of invasive aspergillus and candida infections in high-risk patients with compromised immune systems
- In June 2021, Mankind Pharma introduced Posaconazole Gastro-Resistant Tablets under the brand name POSAFORCE 100, indicated for treating mucormycosis patients. The product was also approved by the Drug Controller General of India (DCGI) and recommended by guidelines from AIIMS and ICMR for managing mucormycosis. Posaconazole is a USFDA-approved antifungal drug
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Injection, Delayed-release Tablets, Oral Suspension, and Others), Applications (Prophylaxis of Invasive Aspergillus and Candida Infections, Oropharyngeal Candidiasis(OPC), Invasive Infections by Candida, Mucor and Aspergillus Species, and Other), End-Users (Clinics, Hospitals, Diagnostic centres, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Posaconazole Market size was valued at USD 613.48 USD Million in 2024.
The Global Posaconazole Market is projected to grow at a CAGR of 5.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
